BMS Wins Agenus’ anti-TIGIT Asset to Bolster I-O Pipeline
Bristol Myers Squibb’s pioneering record and innovative capabilities in immuno-oncology (I-O) is well known in the industry. Its oncology drug portfolio is larger than that of J&J, Merck and Pfizer …
Read More